Navigation Links
Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting
Date:9/27/2010

on study in mice demonstrated that Ex-RAD dosed orally or by injection prior to lethal whole body irradiation (WBI) produced significant enhancement in survival for both Ex-RAD treated groups versus placebo.

Results from the radiomitigation experiment (where the drug is administered after exposure to lethal radiation), using both injection and oral methods of delivery demonstrated that Ex-RAD treated animals had comparably high rates of survival in both groups.

Hence, oral Ex-RAD was found to be effective in both prophylactic pre-treatment and mitigation post-treatment settings.

"Years of collaborative work are resulting in great progress with Ex-RAD in the laboratory and the clinic and Ex-RAD is the focus of several posters and a key presentation within the RSS scientific and educational track," said Manoj Maniar, PhD, Senior Vice President for Product Development of Onconova. "We are very excited to see the acceleration and new developments within radioprotection, specifically in oral prophylaxis and treatment. Ex-RAD holds a unique position among developing products with the potential to benefit people exposed to whole body radiation."

Onconova oral presentation and poster sessions on Ex-RAD at the Radiation Research Society meeting:

Oral Presentation

WEDNESDAY, SEPTEMBER 29, 2010

  • No. MS701 (Mini-Symposium Presentation, 10:15 AM-12:15 PM) Radioprotection and Radiomitigation Properties of Ex-RAD Upon Oral Administration Manoj Maniar1, Ramesh Kumar1, Bo-Hyun Moon2, David Taft3, Kamal Datta2; 1Onconova Therapeutics, Inc., 2Georgetown University, Department of Biochemistry and Molecular & Cellular Biology and Lombardi Comprehensive Cancer Center, 3Long Island University, Arnold & Marie Schwartz College of Pharmacy

Poster Sessions Radiation Protection Protection / Mitigators / Treatment

SUNDAY, SEPTEMBER 26, 2:00 pm-2:45 pm, 2010, Haleakala Foyer

'/>"/>

Contact: Katrhyn Morris
kathryn@proncall.com
845-635-9828
PR on Call
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
2. Study says therapeutics for trauma patients may not be effective due to an infection
3. Cambridge Healthtech Announces Its Inaugural Encouraging Development of Therapeutics for Neglected Diseases Conference
4. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
5. ACS Webinar focuses on drug discovery process for small molecule therapeutics
6. Talecris Biotherapeutics Hires Nimish Shah as Vice President, Federal Government Relations
7. US Patent Granted To Chrono Therapeutics Inc. For Its Chrono-Pharmacological Drug Delivery Systems And Applications
8. JDP Therapeutics, Inc. Appoints Christopher M. Cashman to Board of Directors
9. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
10. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
11. FAB-HOMES™ Presents First Passive House Collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... damage to the ends of chromosomes could hold the key ... form of skin cancer according to new research from ... an important new genetic risk factor for melanoma. , It ... strongest indicators of those most at risk of developing melanoma. ... sun, as they burn more easily. , It now appears ...
(Date:9/17/2014)... North Central Surgical Center is proud to ... their top-notch services. The hospital was the recipient for ... surgery. , Hospital-wide, North Central was the recipient of ... this award for two years in a row (2013-2014). ... the nation for Patient Safety in 2014 and ranked ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Tidewater ... host recruit757’s scholarship workshop for football players and their ... Sept. 23. , Doors open at 6:30 p.m. for ... and speak to trainers and physical therapists. The workshop ... p.m. , The Newport News Tidewater Performance Center, which ...
(Date:9/17/2014)... Positive messages about the health benefits of quitting smoking ... study suggests. Although smokers who think quitting will ... harmful effects of smoking, researchers found smokers who believe ... "gain-framed," or positive, messages about how quitting will improve ... mix of both types of messages might get more ...
(Date:9/17/2014)... FRISCO, Texas (PRWEB) September 17, 2014 ... (EV-D68) outbreak that is hospitalizing scores of infants, children ... Louisiana, says Dr. Kirk Mahon, medical director of Legacy ... , “There have been no reported cases of EV-D68 ... Oklahoma and Louisiana, that could change,” he said. “Implementing ...
Breaking Medicine News(10 mins):Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2
... Medical Transcription announced today that Administrative Advantage has chosen ZyDoc,s ... , ... Hauppauge, New York (PRWEB) May ... that Administrative Advantage , a full-service medical transcription company ...
... Robert L. Williamson III, DDS of Raleigh Comprehensive and Cosmetic Dentistry ... to earn the certification for oral sedation dentistry. , ... ... Cosmetic Dentistry, Dr. Robert L. Williamson III and Associates, announced recently ...
... Access to Pixantrone through ProgramSEATTLE, May 5 Cell ... that pixantrone is now available on a named-patient basis ... healthcare professionals for the treatment of individual patients with ... standard therapies or is refractory to them. We know ...
... to Colleges and Universities , ... Baltimore, MD. (Vocus) ... has formally completed the acquisition of CMI Insurance, formerly a PSA ... Inc., the travel medical insurance entity within MEDEX Global ...
... Growth and Effective Expense ManagementContinued Progress on Debt ReductionBIRMINGHAM, ... HLS ) today reported its results of operations for ... showed consolidated net operating revenues of $475.1 million for ... for the first quarter of 2008, or an increase ...
... Every summer, valley businesses shed their business attire in exchange ... in the spirit of raising money for United Cerebral Palsy ... disabilities. This year, the theme is Camp Casual and ... 17th though businesses can choose to hold their event on ...
Cached Medicine News:Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 2Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 3Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 4Health News:Raleigh Comprehensive and Cosmetic Dentistry Earns Certification For Sedation Dentistry 2Health News:Raleigh Comprehensive and Cosmetic Dentistry Earns Certification For Sedation Dentistry 3Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 2Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 3Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 4Health News:MEDEX Acquires CMI Insurance 2Health News:MEDEX Acquires CMI Insurance 3Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 2Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 3Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 4Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 5Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 6Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 7Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 8Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 9Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 10Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 11Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 12Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 13Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 14Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 15Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 16Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 17Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 18Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 19Health News:Valley Businesses Shedding Their Suits to Go Casual for a Cause 2
(Date:9/17/2014)... Sept. 17, 2014 Pomerantz LLP is investigating ... ("PDL BioPharma" or the "Company") (NASDAQ: PDLI).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On September 17, 2014, the Company ...
(Date:9/17/2014)... 17, 2014  Rebiotix Inc. announced this morning that results ... candidate, RBX2660 (microbiota suspension) will be presented in two posters ... Philadelphia from October 8-12. ... poster session on Thursday, October 9, 2014: Poster: ... 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study ...
(Date:9/17/2014)... , Sept. 17, 2014  Bayer HealthCare will present ... Foundation,s 66 th Annual Meeting, which takes place ... The data, which will be shared through poster presentations, ... patient care. Data will be presented in a scientific ... treatment modalities in hemophilia A patients, Bayer is maintaining ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4
...   , Strategic collaboration with Ipsen for marketing ... Nordics and the US , Photocure to commercialise ... Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on ... of a new commercial strategy for Hexvix, its flagship product ...
... Luminex Corporation (NASDAQ: LMNX ), today ... its annual European multiplexing technology symposium, September 28-29, 2011, ... feature scientific sessions, workshops, discussion groups, exhibitions and networking ... who are performing groundbreaking work in clinical diagnostics and ...
Cached Medicine Technology:Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 2Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 3Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 4Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 5Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 6Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 7Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 8Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 4
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
... an effort to improve on the ... toxicology, abused drugs, and immunosuppressants tests, ... which incorporates random access capabilities. Although ... undergone several important changes in the ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Medicine Products: